AstraZeneca Plc (NASDAQ:AZN) and Merck & Co Inc (NYSE:MRK), on Wednesday, announced long-term results from the OlympiA Phase ...

AstraZeneca and MSD's PARP inhibitor Lynparza has improved long-term survival when given as adjuvant therapy for early breast ...

AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term results ...

AstraZeneca (AZN) and Merck (MRK) reported positive long-term survival data for their drug Lynparza in the treatment of ...

Project EVOLVE, funded by Daiichi Sankyo and AstraZeneca, to be presented at the 2024 San Antonio Breast Cancer Symposium -- NEW YORK, Dec. 12, 2024 /PRNewswire/ -- Novellia, Inc., an AI-enabled ...

Lynparza demonstrates sustained survival benefits in Phase III OlympiA breast cancer trial, reducing death risk by 28% over ...

Patients with germline BRCA mutations who were diagnosed with breast cancer at or before age 40 and who underwent a bilateral risk-reducing mastectomy (RRM) and/or a risk-reducing ...

The benefit of the PARP inhibitor in patients with germline BRCA pathogenic variants remains evident 10 years after the first ...

China: Enhertu, a blockbuster breast cancer drug of AstraZeneca, will be included in China's state-run health insurance ...

AstraZeneca's blockbuster breast cancer drug will be added to China's national reimbursement scheme list, according to an ...

Imlunestrant, an investigational next-generation selective estrogen receptor degrader (SERD), improved progression-free survival in patients with endocrine therapy-pretreated, ER-positive, ...

Enhertu won its initial China nod in early 2023 as a treatment for previously treated HER2-positive breast cancer and later ...